See more : Canfor Pulp Products Inc. (CFPUF) Income Statement Analysis – Financial Results
Complete financial analysis of Shop Apotheke Europe N.V. (SAEYY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Shop Apotheke Europe N.V., a leading company in the Medical – Pharmaceuticals industry within the Healthcare sector.
- Mangalam Organics Limited (MANORG.NS) Income Statement Analysis – Financial Results
- Prakit Holdings Public Company Limited (PRAKIT.BK) Income Statement Analysis – Financial Results
- First Hotels AB (publ) (HOTEL.ST) Income Statement Analysis – Financial Results
- BioVie Inc. (BIVI) Income Statement Analysis – Financial Results
- Aprogen Medicines Inc. (007460.KS) Income Statement Analysis – Financial Results
Shop Apotheke Europe N.V. (SAEYY)
About Shop Apotheke Europe N.V.
Shop Apotheke Europe N.V. owns and operates online pharmacies in Germany, Austria, Switzerland, France, Belgium, Italy, and the Netherlands. It provides prescription medications, over-the-counter medications, and pharmacy-related beauty and personal care products, as well as food supplements. The company was founded in 2001 and is headquartered in Sevenum, the Netherlands.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.80B | 1.20B | 1.06B | 968.06M | 701.01M | 539.71M | 283.99M | 177.39M | 125.58M | 84.67M | 55.29M |
| Cost of Revenue | 1.36B | 872.57M | 793.79M | 748.53M | 563.33M | 440.39M | 226.41M | 141.11M | 99.84M | 66.64M | 42.55M |
| Gross Profit | 440.38M | 331.79M | 266.53M | 219.53M | 137.68M | 99.32M | 57.58M | 36.28M | 25.74M | 18.04M | 12.75M |
| Gross Profit Ratio | 24.48% | 27.55% | 25.14% | 22.68% | 19.64% | 18.40% | 20.28% | 20.45% | 20.49% | 21.30% | 23.05% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 33.00M | 26.51M | 21.25M | 19.39M | 15.51M | 13.79M | 8.98M | 4.61M | 4.14M | 1.92M | 1.24M |
| Selling & Marketing | 234.44M | 217.73M | 175.63M | 125.85M | 93.20M | 67.63M | 46.66M | 28.69M | 20.89M | 13.07M | 8.36M |
| SG&A | 267.44M | 244.24M | 196.88M | 145.24M | 108.71M | 81.42M | 55.64M | 33.30M | 25.03M | 15.00M | 9.59M |
| Other Expenses | 190.24M | 0.00 | 0.00 | 65.00K | 136.00K | 196.00K | 3.02M | 2.20M | 1.32M | 928.00K | 673.00K |
| Operating Expenses | 457.68M | 401.11M | 309.94M | 220.46M | 171.86M | 128.24M | 79.80M | 50.13M | 35.87M | 23.01M | 15.30M |
| Cost & Expenses | 1.82B | 1.27B | 1.10B | 968.99M | 735.19M | 568.64M | 306.20M | 191.23M | 135.71M | 89.65M | 57.84M |
| Interest Income | 4.61M | 274.00K | 28.00K | 93.00K | 112.00K | 324.00K | 40.00K | 17.00K | 593.00K | 0.00 | 0.00 |
| Interest Expense | 15.46M | 8.50M | 8.57M | 10.41M | 7.48M | 6.19M | 2.25M | 9.34M | 2.28M | 826.00K | 839.00K |
| Depreciation & Amortization | 57.29M | 39.51M | 26.92M | 16.06M | 14.61M | 13.17M | 7.06M | 3.27M | 2.17M | 1.66M | 1.13M |
| EBITDA | 50.94M | -36.10M | -19.91M | 10.89M | -19.83M | -17.98M | -12.10M | -8.35M | -6.06M | -2.39M | -752.00K |
| EBITDA Ratio | 2.83% | -2.76% | -1.88% | 1.13% | -2.91% | -2.82% | -4.26% | -4.71% | -4.83% | -2.83% | -1.36% |
| Operating Income | -17.30M | -69.17M | -65.70M | -866.00K | -33.45M | -28.73M | -19.20M | -11.64M | -8.82M | -4.05M | -1.88M |
| Operating Income Ratio | -0.96% | -5.74% | -6.20% | -0.09% | -4.77% | -5.32% | -6.76% | -6.56% | -7.02% | -4.78% | -3.40% |
| Total Other Income/Expenses | 2.95M | -14.95M | -12.19M | -15.07M | -8.74M | -5.86M | -2.21M | -9.32M | -1.68M | -826.00K | -839.00K |
| Income Before Tax | -14.35M | -84.12M | -77.88M | -15.93M | -42.18M | -34.59M | -21.40M | -20.96M | -10.50M | -4.87M | -2.72M |
| Income Before Tax Ratio | -0.80% | -6.98% | -7.35% | -1.65% | -6.02% | -6.41% | -7.54% | -11.82% | -8.36% | -5.76% | -4.91% |
| Income Tax Expense | -2.74M | -6.47M | -3.70M | 839.00K | -5.91M | -982.00K | -45.00K | -2.52M | 47.00K | 161.00K | 113.00K |
| Net Income | -12.04M | -77.65M | -74.19M | -16.77M | -36.27M | -33.61M | -21.36M | -18.45M | -10.55M | -5.04M | -2.83M |
| Net Income Ratio | -0.67% | -6.45% | -7.00% | -1.73% | -5.17% | -6.23% | -7.52% | -10.40% | -8.40% | -5.95% | -5.12% |
| EPS | -0.63 | -4.32 | -4.15 | -1.17 | -2.78 | -0.28 | -0.22 | -0.20 | -0.12 | -0.06 | -0.03 |
| EPS Diluted | -0.63 | -4.32 | -4.15 | -1.17 | -2.78 | -0.28 | -0.22 | -0.20 | -0.12 | -0.06 | -0.03 |
| Weighted Avg Shares Out | 19.24M | 17.98M | 17.88M | 14.38M | 13.06M | 120.46M | 94.98M | 90.70M | 90.70M | 90.70M | 90.70M |
| Weighted Avg Shares Out (Dil) | 19.24M | 17.98M | 17.88M | 14.38M | 13.06M | 120.46M | 94.98M | 90.70M | 90.70M | 90.70M | 90.70M |
Redcare Pharmacy NV (SAEYY) Q3 2024 Earnings Call Transcript
Source: https://incomestatements.info
Category: Stock Reports